BioBay, the Suzhou life science park, announced a drug research collaboration with Roche and Harvard University. Harvard scientists will contribute a novel research approach to the project for a cancer drug that is built around autophagy, the degradation of cell components. BioBay will add expertise in medicinal chemistry and preclinical development, and Roche will provide access to its drug discovery, development and commercialization capabilities. The project will be implemented and managed by the newly established Nimbus Innoworks, a joint-venture between BioBay and Wen Associates. More details....

Stock Symbol: (SIX: ROG)     Share this with colleagues: